US Liraglutide Injection Market Insight
The US Liraglutide Injection market size is growing at a 8.1% CAGR, driven by increasing electricity demand, grid modernization initiatives, and rising integration of renewable energy sources into the national grid infrastructure.
U.S. Liraglutide Injection Market Insights Forecasts to 2035
- The US Liraglutide Injection Market Size Was Estimated at USD 6.88 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.36% from 2025 to 2035
- The US Liraglutide Injection Market Size is Expected to Reach USD 15.35 Billion by 2035
Notable Insights for U.S. Liraglutide Injection Market
- By service type, the branded liraglutide segment dominated the market, generating approximately USD 0.58 Billion in revenue in 2024.
- By application, the type 2 diabetes treatment segment is expected to witness the fastest growth, supported by continued use in glycemic control despite increasing competition from newer therapies.
- Approximately 60% of liraglutide demand is driven by diabetes management, while nearly 30% is attributed to obesity treatment applications, reflecting its dual therapeutic use. Additionally, the US accounts for a significant share in the North American liraglutide market due to high disease prevalence.
- Increasing shift toward next-generation GLP-1 receptor agonists is restraining the US liraglutide injection market, as newer drugs offer superior efficacy, longer dosing intervals, and improved patient adherence.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Liraglutide Injection market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Liraglutide Injection Market
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd.
- Biocon Limited
- Eli Lilly and Company
- Sanofi S.A.
- Pfizer Inc.
- Merck & Co., Inc.
- AstraZeneca PLC
- Others
Recent Developments:
- In February 2026, Biocon Limited announced plans to launch a generic version of liraglutide in the US, aiming to provide cost-effective alternatives and expand patient access amid rising competition in the GLP-1 segment.
- In August 2025, Teva Pharmaceutical Industries Ltd. introduced a generic liraglutide injection for weight management, increasing market competition and reducing treatment costs for patients in the US.
Market Segmentation:
United States Liraglutide Injection Market, By Product Type
- Branded
- Generic
United States Liraglutide Injection Market, By Application
- Type 2 Diabetes
- Obesity Management
- Others
United States Liraglutide Injection Market, By End User
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
Expert Views:
The US liraglutide injection market is expected to witness a gradual decline, influenced by rapid adoption of next-generation GLP-1 therapies and increasing availability of generics. Experts highlight that while diabetes applications will sustain baseline demand, pricing pressures and therapeutic substitution will significantly reshape the market landscape over the forecast period.